The Great AI Wrapper Charade in Biotech
In boardrooms and biotech conferences alike, one phrase has become inescapable: “our AI-powered platform.” Startups in drug discovery, clinical decision
Company of the week: Poxel SA: Navigating Judicial Reorganization While Clinical Assets Retain Promise
Poxel SA, a French biopharmaceutical company that successfully developed and commercialized the first-in-class diabetes drug TWYMEEG® in Japan, filed for
Fund of the week: OrbiMed Royalty & Credit Opportunities
Executive Summary
OrbiMed's Royalty & Credit Opportunities strategy has emerged as a prominent non-dilutive financing platform in the
Venture Debt in Biotech & Pharma: A 2025 Comprehensive Analysis
Venture Debt in Biotech & Pharma: A 2025 Deep Dive
Introduction: The Rise of Biotech Venture Debt
Venture debt has
Pharmaceutical Royalty Structures: A Global Technical Analysis
Executive Summary
In the pharmaceutical industry, royalties serve as a fundamental mechanism for sharing value from intellectual property and products.
Lilly’s TuneLab: accelerator, equaliser—or a gilded cage?
Eli Lilly’s latest act of corporate altruism arrived in September 2025 in the form of TuneLab, an artificial intelligence
The weekly term sheet (37)
Pharmaceutical & Biotech Transactions: September 8-14, 2025
Executive Summary
The week of September 8-14, 2025 witnessed 22 verified transactions in
Fractional Biotech Equity: From Experimental Concept to $1.3 Billion Alternative Funding Mechanism
Fractional equity funding for biotech companies - achieved through traditional securities divided into smaller units rather than cryptocurrency - has
Company of the week: Absci Corporation
Absci Corporation (NASDAQ: ABSI) stands at a pivotal crossroads in September 2025, having transitioned from a pure AI drug discovery
Fund of the Week: Neo Kuma Ventures – Europe's Psychedelic Medicine Specialist
Executive Summary
Neo Kuma Ventures, established in December 2020 as Europe's first venture fund dedicated to psychedelic healthcare,
